Mayo Clinic receives patent for GeneSight

Share this article:

 

The Mayo Clinic has received a patent for a new medication selection procedure. GeneSight uses a test to prioritize the selection of medications for patients with depression, chronic pain and other psychiatric disorders.

 

GeneSight tests for genetic variants that affect a patient's response to psychotropic and analgesic medications, allowing clinicians to make evidence-based decisions about drug selection.

 

The company said the tool should help skilled nursing facilities reduce their use of antipsychotics.

Share this article:
close

Next Article in Products

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.